Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Colorectal Cancer Screening, Colorectal Cancer Metastatic, Colon Adenocarcinoma
Interventions: Not listed
Lead sponsor: Mainz Biomed; Industry
Eligibility: 18 Years and older
Enrollment: 2,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Interventions: Delgocitinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Bronchoscopic Interventions
Interventions: Single use bronchoscope; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 45
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Rebound Pain, Shoulder Arthroplasty, Interscalene Block
Interventions: Bupivacaine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breathing, Lung Function Decreased, MRI Imaging, Healthy
Interventions: Airway Oscillometer, Phase Resolved Functional Lung MRI; Device · Diagnostic Test
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Merkel Cell Carcinoma
Interventions: Pembrolizumab, Lutetium Lu 177 dotatate; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Duarte, California • Iowa City, Iowa • New York, New York + 1 more

Conditions: Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
Interventions: Cemiplimab, XL092; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina

Conditions: Peripheral Arterial Disease
Interventions: Exercise Intervention, VAPAHCS Rehabilitation Core Components; Other
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Obesity & Overweight, Obesity (Disorder)
Interventions: Positive Reinforcement, Positive Reinforcement + Areas for Change; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
Interventions: Obrixtamig, Pumitamig, Carboplatin, Etoposide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • East Brunswick, New Jersey + 2 more

Conditions: Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions: Microscope integrated optical coherence tomography; Device
Lead sponsor: Duke University; Other
Eligibility: 4 Weeks and older
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Leukocyte Adhesion Deficiency
Interventions: AVTX-803; Drug
Lead sponsor: AUG Therapeutics; Industry
Eligibility: 6 Months to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer Screening, Lung Neoplasms, Smoking ( Cigarette), Early Detection of Cancer
Interventions: Empower LCS, Call+ Telephone Navigation, Usual Care, Education; Behavioral · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 50 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 57
States / cities: Anaheim, California • Costa Mesa, California • Irvine, California + 27 more

Conditions: Triple-Negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab tirumotecan, Capecitabine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 93
States / cities: Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more

Conditions: Colorectal Cancer, Bladder Cancer
Interventions: Telehealth Intervention, Standard of care; Behavioral · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Obesity, Insulin Sensitivity, Muscle Weakness, Adiposity, Insulin Resistance
Interventions: Diet Weight Loss; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Interventions: Lirafugratinib; Drug
Lead sponsor: Elevar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more

Conditions: Thromboangiitis Obliterans (Buerger's Disease)
Interventions: ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g), Placebo; Biological · Other
Lead sponsor: Antidote Therapeutics, Inc; Industry
Eligibility: 23 Years to 59 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: NSCLC Stage IV, NSCLC, Recurrent
Interventions: Atezolizumab; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Fairway, Kansas • Kansas City, Kansas

Conditions: Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Rochester, New York

Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 8
States / cities: Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Critical Illness
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Bethesda, Maryland • Durham, North Carolina

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Single Use Bronchoscopes for Interventional Pulmonology

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Effect of Local Anesthetic Concentration on Rebound Pain

Phase Resolved Functional Lung MRI and Oscillometry for the Observation of Healthy Lung Function

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Prehabilitation and Rehabilitation in PAD

Examining Valence-based Effects in Self-Monitoring Feedback Messages

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

Intraoperative OCT Guidance of Intraocular Surgery II

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II

Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Telehealth Intervention for Ostomy Self-Management

Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

SC2i Tissue and Data Repository Protocol

Analysis of Human ALS Tissues and Registry of ALS Patients